IGM-8444 is under clinical development by IGM Biosciences and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how IGM-8444’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
IGM-8444 is under development for the treatment of relapsed or refractory non-Hodgkin’s lymphoma, solid tumors including colorectal cancer, sarcoma and relapsed or refractory chronic lymphocytic leukemia and acute myeloid leukemia. The drug candidate acts by targeting death receptor 5 (DR5). It is administered through intravenous route.It was also under development for the treatment of metastatic prostate cancer, gastric cancer, ovarian cancer, non-small cell lung cancer.
IGM Biosciences overview
IGM Biosciences operates as a biotechnology company that develops novel antibodies for the treatment of cancer and other diseases. The company’s pipeline product portfolio includes IGM-2323is an IgM-based CD20 x CD3 bispecific antibody T cell engager, IGM-8444 is an IgM antibody targeting Death Receptor, IGM-7354 is a targeted IL-15 immune stimulating antibody and IGM-2644 is a T cell engaging IgM antibody targeting CD38 for the treatment of patients with multiple myeloma. It utilizes IgM and IgA antibodies technology for developing their products. The company serves in the therapeutic areas of immuno oncology. IGM Biosciences is headquartered in Mountain View, California, the US.
For a complete picture of IGM-8444’s drug-specific PTSR and LoA scores, buy the report here.